Article Details

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns "Buy" Rating from Chardan Capital

Retrieved on: 2021-07-10 11:32:37

Tags for this article:

Click the tags to see associated articles and topics

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns "Buy" Rating from Chardan Capital. View article details on hiswai:

Excerpt

The biotechnology company reported ($0.65) EPS for the quarter, topping the Zacks' consensus estimate of ($0.69) by $0.04. During the same period ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up